Respiratory

Addressing the complexity of respiratory research

Pushing boundaries in idiopathic pulmonary fibrosis clinical research

Idiopathic pulmonary fibrosis (IPF) is a progressive and life-limiting lung disease characterised by scarring (fibrosis) of the lung tissue which primarily affects older adults. The exact cause of the disease is unknown, however, certain risk factors, such as a history of smoking, and genetic predisposition, may increase the likelihood of developing the disease.

Read the whitepaper
SVG Image
thumbnail

Therapeutic Focus - Pushing Boundaries in Idiopathic Pulmonary Fibrosis Clinical Research

With more than 170 early stage IPF clinical programs, IPF is one of the most dy­namic rare diseases spaces for development.

Read the article
SVG Image
woman with pulmonary scan

Pushing boundaries in idiopathic pulmonary fibrosis clinical research

The landscape of IPF research is evolving and early-stage biopharmaceutical teams need a new roadmap to success. We offer strategies to meet the challenges to develop new treatments.

Read the blog
SVG Image
Physician discussing treatment options with patient

Pandemic respiratory vaccine clinical trials: A departure from business as usual

Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.

Read the whitepaper
SVG Image
COVID-19 vaccine component visual